Immune therapy in autoimmune encephalitis: a systematic review

Area of Science:

• Neuroimmunology
• Neurology

Background:

• Autoimmune encephalitis involves antibodies targeting cell surface antigens like N-methyl-D-aspartate receptor (NMDAR).
• Current literature primarily consists of retrospective studies, lacking randomized controlled trials.

Purpose of the Study:

• To review and synthesize the existing literature on immunotherapy for autoimmune encephalitis.
• To identify emerging therapeutic themes and treatment effectiveness.

Main Methods:

• Literature review of studies on autoimmune encephalitis with antibodies to various cell surface antigens.
• Analysis of treatment strategies, including first-line (steroids, IVIg, plasma exchange) and second-line (rituximab, cyclophosphamide) therapies.
• Consideration of tumor removal when applicable.

Main Results:

• Patients receiving immunotherapy demonstrate improved outcomes and reduced relapse rates compared to untreated patients.
• Early treatment initiation is associated with better patient prognosis.
• Second-line immunotherapy effectively improves outcomes and decreases relapses in cases refractory to first-line treatment.

Conclusions:

• Immunotherapy is a beneficial treatment for autoimmune encephalitis.
• Timely and appropriate escalation of therapy (first-line and second-line) is critical for managing autoimmune encephalitis.
• Acknowledging inherent biases in retrospective data is essential for interpreting findings.